Shots: The agreement is focus on developing and commercializing ARO-HBV that can improve QoL for chronic hepatitis B It includes drug candidate ARO-HBV along with option to license three additional treatments for Hepatitis B Arrowhead to get an upfront $175M with $1.6B milestone payments for ARO-HBV. $1.9B in option and milestone payments for the three […]Read More
